Published in
Wiley, Pigment Cell & Melanoma Research, 4(31), p. 534-540, 2018
DOI: 10.1111/pcmr.12694
Links
Tools
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
Journal article published in 2018 by
Janice M. Mehnert 
,
Ann W. Silk,
J. H. Lee,
Liesel Dudek,
Byeong-Seon Jeong,
Jiadong Li,
Jason M. Schenkel,
Evita Sadimin,
Michael Kane,
Hongxia Lin,
Weichung J. Shih,
Andrew Zloza ,
Suzie Chen,
James S. Goydos
,
Ann W. Silk,
J. H. Lee,
Liesel Dudek,
Byeong-Seon Jeong,
Jiadong Li,
Jason M. Schenkel,
Evita Sadimin,
Michael Kane,
Hongxia Lin,
Weichung J. Shih,
Andrew Zloza ,
Suzie Chen,
James S. Goydos
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 